Latest news...

On August 21, 2019, the Board of Directors approved NMIN's initial …
Over 100 delegates—researchers, trainees, partner organization representatives and other stakeholders—gathered at …
UBC attracts over $40M to host Networks of Centres of Excellence …
NMIN

about us

Advancing research, innovation and training in nanomedicines to maintain Canada as the world leader in the field.

The NanoMedicines Innovation Network (NMIN) is advancing “smart” medicines to cure disease by delivering small molecule drugs more specifically to disease sites and enabling the clinical use of gene therapies.

NMIN brings 60 Principal Investigators from 17 institutions across Canada together with 15 companies and 8 not-for-profit research and granting institutions in a network committed to expanding and improving Canada’s position as a global leader in nanomedicines R&D.

NMIN is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.

NMIN

Our focus

Develop nanomedicines

that enhance the therapeutic properties of small molecule drugs, and enable gene therapies.

Develop new diagnostics

that enable more precise disease detection and treatment, based on nanotechnology.

Train scientists

in the technology and business of nanomedicines, guided by market needs for HQP with skills required by the R&D community.

Translate nanomedicine

products and technologies, by implementing a cohesive IP and commercialization strategy.

NMIN

Management Team

Pieter Cullis

Scientific Director

Gilbert Walker

Associate Scientific Director

Diana Royce

Executive Director

NMIN

Contact

NMIN

2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
info@nanomedicines.ca

NMIN

2350 Health Sciences Mall, Room 5451 | University of British Columbia | Vancouver, BC V6T 1Z3 Canada
info@nanomedicines.ca